NCT05123196已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 156
- 试验地点
- 33
- 主要终点
- Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period
研究概览
简要总结
The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of MT-8554, compared to placebo, in subjects with painful diabetic peripheral neuropathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with written consent
- •Patients aged >=20 years at the time of consent
- •Outpatients
- •Patients with pain associated with peripheral symmetric polyneuropathy due to diabetes mellitus and pain lasting >=3 months on the first day of the run-in period. The patient should meet >=2 of the following criteria or nerve conduction studies showing abnormalities in at least one test item (Conduction velocity, amplitude, and latency) for at least two nerves by the first day of run-in period.
- •1. Subjective symptoms* thought to be due to diabetic polyneuropathy
- •2. Decreased or eliminated bilateral Achilles tendon reflexes
- •3. Bilateral decreased vibratory sense of the medial malleolus (=< 10 seconds with a C 128 tuning fork)
- •*Subjective symptoms thought to be due to diabetic neuropathy meet the following 3 criteria.
- •Bilateral
- •Toe and plantar symptoms (Numbness, pain or dysesthesia)
- •Does not cause upper extremity symptoms alone
- •Patients whose NRS during the run-in period is assessed for >=4 days of the 7 days immediately before the first day of the treatment period and whose baseline 24-hour mean NRS score is >=4 and =<
- •Patients whose rate of change in the 24-hour mean NRS score during the 7 days immediately before the first day of the treatment period is <30%.
- •Patients whose treatment for diabetes mellitus is consistent >=8 weeks before the run-in period, who can consistently maintain the treatment throughout the study period, and in whom the investigator (or sub-investigator) can determine that glycemic control is constant.
排除标准
- •Patients with pain, disease, or skin condition that, in the opinion of the investigator (or sub-investigator), would influence the evaluation of painful diabetic peripheral neuropathy.
- •For example, if other pain is in the same location as painful diabetic peripheral neuropathy, or if the pain intensity of the other pain is greater than that of painful diabetic peripheral neuropathy, which in the opinion of the investigator (or sub-investigator) would impact the assessment of painful diabetic peripheral neuropathy.
- •Patients who have had amputation of upper and lower limbs other than toes due to gangrene caused by impaired blood circulation.
- •Patients who do not meet the criteria of prohibited concomitant drugs or restricted concomitant drugs.
- •Patients with hypersensitivity to acetaminophen or a history of hypersensitivity to acetaminophen.
- •Patients with New York Heart Association functional class III or IV symptoms of heart failure.
- •History of myocardial infarction, congestive heart failure, unstable angina, or cerebrovascular disorder (excluding lacunar infarction) within 6 months prior to informed consent.
- •Patients with major psychiatric disorder such as depression or anxiety disorder.
- •Patients with drug abuse or a history of drug abuse.
- •Patients with current or previous infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). However, patients with previous infection with hepatitis B virus who are HBsAg-negative are eligible.
- •Patients with HbA1c > 10.5%.
- •Patients with poorly controlled hypertension (>= 180 mmHg systolic and/or >= 110 mmHg diastolic).
- •Patients with eGFR < 30 mL/min/1.73 m^
- •Patients with AST or ALT > 2.5*ULN.
- •Patients who answered "Yes " to any item of Columbia Suicide Severity Rating Scale within the past 12 months.
- •Patients who have a concomitant malignancy or a history of malignancy. However, patients who have a history of malignancy but have not experienced recurrence for at least 5 years before informed consent (patients who have not experienced recurrence for at least 5 years after the last administration if the patients were receiving anticancer drugs) will be excluded.
- •Male or female patients of childbearing potential who do not agree to use contraception from the date of informed consent until 3 months after the completion (discontinuation) of investigational product.
- •Female patients who are pregnant, breastfeeding or possibly pregnant.
- •Patients who participated in another clinical study and received investigational product within 12 weeks before informed consent.
- •Prior exposure to MT-
- •Other patients who, in the opinion of the investigator (or sub-investigator), are ineligible for this study.
研究组 & 干预措施
MT-8554
Experimental
MT-8554 will be started from a low dose, and gradually increase the dose in order.
干预措施: MT-8554 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period
时间窗: Baseline and Week 12
Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.
次要结局
- Change from baseline in weekly mean nocturnal average NRS score at each assessment point(Up to Week 12)
- Proportion of PGIC responders at each assessment point(Up to Week 12)
- Change from baseline in weekly mean 24 hour worst NRS score at each assessment point(Up to Week 12)
- Change from baseline in BPI functional impairment at each assessment point(Up to Week 12)
- Change from baseline in weekly mean 24-hour average NRS score at each assessment point(Up to Week 12)
- Average weekly 24-hour NRS score during the 12 week treatment period 30% and 50% responder rates(Baseline and Week 12)
- Change from baseline in weekly mean daily NRS score at each assessment point(Up to Week 12)
- Change from baseline in NPSI at each assessment point(Up to Week 12)
- Change from baseline in BPI pain severity at each assessment point(Up to Week 12)
- Change from baseline in MOS-SS at each assessment point(Up to Week 12)
- Proportion of CGIC responder at each assessment point(Up to Week 12)
研究者
研究点 (33)
Loading locations...
相似试验
已完成
1 期
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy SubjectsThrombosisNCT03197779Bristol-Myers Squibb691
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese ParticipantsHealthy VolunteersNCT05813717Bristol-Myers Squibb25
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy AdultsHealthy Adult SubjectsNCT04629131Zhuhai Trinomab Pharmaceutical Co., Ltd.32
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy AdultsHealthy VolunteersNCT05842798Zhuhai Trinomab Pharmaceutical Co., Ltd.28
已完成
1 期
A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT04594928Galapagos NV30